[Current status of therapeutic approaches with targeted therapies in malignant thyroid cancer. Highlights from the 2011 ASCO Congress].
Standard
[Current status of therapeutic approaches with targeted therapies in malignant thyroid cancer. Highlights from the 2011 ASCO Congress]. / Uecker, Florian C.; Laban, Simon; Knecht, Rainald.
In: HNO, Vol. 60, No. 5, 5, 2012, p. 398, 400-403.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - [Current status of therapeutic approaches with targeted therapies in malignant thyroid cancer. Highlights from the 2011 ASCO Congress].
AU - Uecker, Florian C.
AU - Laban, Simon
AU - Knecht, Rainald
PY - 2012
Y1 - 2012
N2 - Increasing interest in the treatment of locally advanced and already metastasized thyroid cancer is reflected in the high number of submitted and accepted conference papers at the annual meeting of the American Society of Clinical Oncology (ASCO Congress) 2011. Many patients suffering from differentiated, undifferentiated and medullary thyroid cancer do not respond to established therapeutic procedures, so that new strategies have to be developed. Targeted biological agents are a new and promising therapeutic method that selectively affects complex signaling cascades, especially angiogenesis, of the malignant cells. Clinicians and researchers should understand the potential of these therapeutic strategies and be aware of the typical side effects.
AB - Increasing interest in the treatment of locally advanced and already metastasized thyroid cancer is reflected in the high number of submitted and accepted conference papers at the annual meeting of the American Society of Clinical Oncology (ASCO Congress) 2011. Many patients suffering from differentiated, undifferentiated and medullary thyroid cancer do not respond to established therapeutic procedures, so that new strategies have to be developed. Targeted biological agents are a new and promising therapeutic method that selectively affects complex signaling cascades, especially angiogenesis, of the malignant cells. Clinicians and researchers should understand the potential of these therapeutic strategies and be aware of the typical side effects.
KW - Humans
KW - Antineoplastic Agents/therapeutic use
KW - Angiogenesis Inhibitors/therapeutic use
KW - Molecular Targeted Therapy/methods/trends
KW - Thyroid Neoplasms/drug therapy
KW - Humans
KW - Antineoplastic Agents/therapeutic use
KW - Angiogenesis Inhibitors/therapeutic use
KW - Molecular Targeted Therapy/methods/trends
KW - Thyroid Neoplasms/drug therapy
M3 - SCORING: Zeitschriftenaufsatz
VL - 60
SP - 398, 400-403
JO - HNO
JF - HNO
SN - 0017-6192
IS - 5
M1 - 5
ER -
